“Prognostic utility of plasma neutrophil gelatinase-associated lipocalin in patients with acute heart failure: The NGAL Evaluation Along with B-type NaTriuretic Peptide in acutely decompensated heart failure (GALLANT) trial.”
…is the name on a recent study published in European Journal of Heart Failure
The bottomline is that IF you use NGAL as a marker along with the standart BNP test, you will be able to determine with much higher certainty, which patients will be likely to endure a re-admission.
It holds unknown potential, but we think that it will add to the future value of having a widely used NGAL test.
